出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年12月
微小残存病変検査市場 : テクノロジー（PCR、フローサイトメトリー、NGS）、用途（白血病、リンパ腫、固形腫瘍）、エンドユーザー（病院、専門クリニック、診断ラボ、研究、学術機関）、地域別 – 2027年までの世界予測
Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region – Global Forecast to 2027
| ページ数 | 175 |
| 図表数 | 161 |
| 種別 | 英文調査報告書 |
| 価格 |
The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period. Market growth is driven by rise in the number of patients with cancer and hematological malignancies, growing awareness drives regarding cancer by government, and increasing collaborations and partnerships between companies.
“The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period”
The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. Device being easy to use, easy accessibility of assay kits, and a good sensitivity are the major factors contributing the large share of this segment.
“Hematological Malignancies applications segment accounted for the highest CAGR”
Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.
“Asia Pacific: The fastest-growing region minimal residual disease testing market”
The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, the presence of a large pool of patient population, the rising focus of key players in the region, government efforts to increase awareness about the detection of diseases, continuously rising healthcare expenditures, an increasing number of hospitals & clinical diagnostic laboratories in India and China, and the strengthening research base for diagnostic procedures across India, China, and Japan.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, Latin America –9%, and the Middle East & Africa – 3%
Lists of Companies Profiled in the Report:
• Labcorp Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Guardant Health (US)
• Sysmex Corporation (Japan)
• NeoGenomics Laboratories, Inc. (US)
• Adaptive Biotechnologies Corporation (US)
• ArcherDX, Inc. (US)
• Asuragen Inc. (US)
• Arup Laboratories Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• Cergentis B.V. (Netherlands)
• Molecular MD (ICON plc) (Ireland)
• Invivoscribe, Inc. (US)
• Mission Bio, Inc. (US)
• Natera, Inc. (US)
• Opko Health, Inc. (US)
• Quest Diagnostics (US)
• Genetron Health (China)
Research Coverage:
This report provides a detailed picture of the global minimal residual disease testing market. It aims at estimating the size and future growth potential of the market across different segments, such as technology, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall minimal residual disease testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
目次
1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 MARKETS COVERED 26
1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION 26
1.3.2 YEARS CONSIDERED 26
1.4 CURRENCY CONSIDERED 27
1.5 LIMITATIONS 27
1.6 STAKEHOLDERS 27
1.7 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.2 RESEARCH APPROACH 29
FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN 29
2.2.1 SECONDARY DATA 30
2.2.1.1 Key data from secondary sources 30
2.2.2 PRIMARY DATA 31
2.2.2.1 Primary sources 32
2.2.2.2 Key data from primary sources 32
2.2.2.3 Key industry insights 33
2.2.2.4 Breakdown of primary interviews 33
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 34
2.3 MARKET SIZE ESTIMATION 34
2.3.1 BOTTOM-UP APPROACH 35
2.3.1.1 Approach 1: Company revenue estimation 35
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 35
2.3.1.2 Approach 2: Presentations of companies and primary interviews 35
2.3.1.3 Growth forecast 36
2.3.1.4 CAGR projections 36
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 36
2.3.2 TOP-DOWN APPROACH 36
FIGURE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH 37
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 38
FIGURE 7 DATA TRIANGULATION METHODOLOGY 38
2.5 MARKET SHARE 39
2.6 STUDY ASSUMPTIONS 39
2.7 GROWTH RATE ASSUMPTIONS 39
2.8 RISK ASSESSMENT 40
2.8.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET 40
3 EXECUTIVE SUMMARY 41
FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 41
FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 42
FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 42
FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 43
4 PREMIUM INSIGHTS 44
4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW 44
FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET 44
4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027 44
FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027 44
4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027 45
FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2027 45
4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2022 VS. 2027 45
FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING 45
4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 46
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
5.2.1 DRIVERS 48
5.2.1.1 Rising incidence of hematological malignancies 48
TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020 48
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 48
5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers 49
5.2.1.3 Increasing cancer awareness initiatives by global health organizations 49
5.2.2 RESTRAINTS 50
5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests 50
5.2.2.2 High cost of minimal residual disease testing kits 50
5.2.3 OPPORTUNITIES 51
5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries 51
TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030 51
5.2.4 CHALLENGES 52
5.2.4.1 Unclear reimbursement scenario and policies for patients 52
5.3 PRICING ANALYSIS 52
TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022) 52
5.4 PATENT ANALYSIS 53
FIGURE 18 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET 53
5.4.1 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 54
5.5 VALUE CHAIN ANALYSIS 54
FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 55
5.6 SUPPLY CHAIN ANALYSIS 56
FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS 56
5.7 ECOSYSTEM/MARKET ANALYSIS 57
FIGURE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM/MARKET ANALYSIS 57
TABLE 5 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM 57
5.8 PORTER’S FIVE FORCES ANALYSIS 58
TABLE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 58
5.8.1 THREAT OF NEW ENTRANTS 58
5.8.2 THREAT OF SUBSTITUTES 58
5.8.3 BARGAINING POWER OF BUYERS 58
5.8.4 BARGAINING POWER OF SUPPLIERS 58
5.8.5 DEGREE OF COMPETITION 59
5.9 REGULATORY ANALYSIS 59
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
5.9.1 NORTH AMERICA 61
5.9.1.1 US 61
5.9.1.2 Canada 61
5.9.2 EUROPE 61
5.9.3 ASIA PACIFIC 61
5.9.3.1 China 61
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 62
5.9.3.2 Japan 63
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 63
5.9.4 LATIN AMERICA 64
5.9.4.1 Brazil 64
5.9.4.2 Mexico 64
5.9.5 MIDDLE EAST 64
5.9.6 AFRICA 64
5.10 TRADE ANALYSIS 65
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS 65
TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017–2021 (USD MILLION) 65
TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017–2021 (USD MILLION) 65
5.11 TECHNOLOGY ANALYSIS 66
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023 66
TABLE 16 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 66
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCT MANUFACTURERS 67
FIGURE 22 REVENUE SHIFT IN MINIMAL RESIDUAL DISEASE TESTING MARKET 68
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 68
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 68
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP THREE APPLICATIONS 68
TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS 69
5.14.2 BUYING CRITERIA 69
FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS 69
TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS 69
5.15 CASE STUDY ANALYSIS 70
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY 71
6.1 INTRODUCTION 72
TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 72
6.2 POLYMERASE CHAIN REACTION 72
6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION 72
TABLE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION) 73
6.3 NEXT-GENERATION SEQUENCING 73
6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET 73
TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION) 74
6.4 FLOW CYTOMETRY 74
6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH 74
TABLE 22 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION) 75
6.5 OTHER TECHNOLOGIES 75
TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 76
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION 77
7.1 INTRODUCTION 78
TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 78
7.2 HEMATOLOGICAL MALIGNANCIES 78
TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020–2027 (USD MILLION) 79
7.2.1 LEUKEMIA 79
TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 80
7.2.1.1 Myeloid leukemia 80
7.2.1.1.1 High prevalence of AML in adults to support growth 80
TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 81
7.2.1.2 Lymphocytic leukemia 81
7.2.1.2.1 High incidence of ALL in children to drive market 81
TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 82
7.2.1.3 Other leukemias 82
TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION) 82
7.2.2 LYMPHOMA 83
TABLE 32 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 33 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 84
7.2.2.1 Non-Hodgkin lymphoma 84
7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth 84
TABLE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 84
7.2.2.2 Hodgkin lymphoma 85
7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing 85
TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 85
7.3 SOLID TUMORS 85
7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH 85
TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2020–2027 (USD MILLION) 86
7.4 OTHER APPLICATIONS 86
TABLE 37 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 86
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER 87
8.1 INTRODUCTION 88
TABLE 38 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 88
8.2 HOSPITALS & SPECIALTY CLINICS 88
8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH 88
TABLE 39 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2020–2027 (USD MILLION) 89
8.3 DIAGNOSTIC LABORATORIES 89
8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH 89
TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 90
8.4 ACADEMIC & RESEARCH INSTITUTES 90
8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET 90
TABLE 41 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 90
8.5 OTHER END USERS 91
TABLE 42 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 91
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION 92
9.1 INTRODUCTION 93
TABLE 43 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 93
9.2 NORTH AMERICA 93
FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT 94
TABLE 44 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 95
TABLE 46 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95
TABLE 47 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 95
9.2.1 US 96
9.2.1.1 Increasing prevalence of cancer to drive market 96
TABLE 48 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 96
TABLE 49 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 97
TABLE 50 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 97
9.2.2 CANADA 97
9.2.2.1 Availability of various cancer screening programs to support market growth 97
TABLE 51 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 98
TABLE 52 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99
TABLE 53 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.3 EUROPE 99
TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020–2035 99
TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 56 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 100
TABLE 57 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 58 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 101
9.3.1 GERMANY 101
9.3.1.1 Government support for research funding to support MRD testing market 101
TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 102
TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 102
TABLE 61 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103
TABLE 62 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 103
9.3.2 UK 103
9.3.2.1 Increasing number of diagnostic laboratories to propel market growth 103
TABLE 63 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 104
TABLE 64 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 104
TABLE 65 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 105
9.3.3 FRANCE 105
9.3.3.1 Rising R&D expenditure in France to drive market 105
TABLE 66 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 105
TABLE 67 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 106
TABLE 68 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 106
9.3.4 ITALY 106
9.3.4.1 Favorable funding scenario to drive market 106
TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020 106
TABLE 70 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 107
TABLE 71 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107
TABLE 72 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 108
9.3.5 SPAIN 108
9.3.5.1 Consolidation of laboratories in Spain to support market growth 108
TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 108
TABLE 74 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109
TABLE 75 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 109
9.3.6 REST OF EUROPE 109
TABLE 76 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 110
TABLE 77 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 78 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 110
9.4 ASIA PACIFIC 111
FIGURE 26 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT 111
TABLE 79 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 80 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 112
TABLE 81 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
TABLE 82 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 113
9.4.1 CHINA 113
9.4.1.1 Growing public access to advanced healthcare facilities to drive market 113
TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020 113
TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 114
TABLE 85 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 86 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 114
9.4.2 JAPAN 115
9.4.2.1 Universal healthcare reimbursement policy to support market growth 115
TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020 115
TABLE 88 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 115
TABLE 89 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 90 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 116
9.4.3 INDIA 116
9.4.3.1 Increasing private and public investments in healthcare system to drive market 116
TABLE 91 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 117
TABLE 92 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117
TABLE 93 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 118
9.4.4 REST OF ASIA PACIFIC 118
TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019 118
TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 119
TABLE 96 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 97 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 119
9.5 LATIN AMERICA 120
9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET 120
TABLE 98 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 120
TABLE 99 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 100 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 121
9.6 MIDDLE EAST & AFRICA 121
9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET 121
TABLE 101 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 122
TABLE 102 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 103 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 123
10 COMPETITIVE LANDSCAPE 124
10.1 OVERVIEW 124
10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN 124
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 124
TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 124
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 127
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 127
10.4 MARKET SHARE ANALYSIS 128
FIGURE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER (2021) 128
TABLE 105 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION 128
10.5 COMPANY EVALUATION QUADRANT 129
10.5.1 LIST OF EVALUATED VENDORS 129
10.5.2 STARS 129
10.5.3 EMERGING LEADERS 129
10.5.4 PERVASIVE PLAYERS 129
10.5.5 PARTICIPANTS 130
FIGURE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021 130
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021) 130
10.6.1 PROGRESSIVE COMPANIES 130
10.6.2 STARTING BLOCKS 131
10.6.3 RESPONSIVE COMPANIES 131
10.6.4 DYNAMIC COMPANIES 131
FIGURE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021 131
10.7 COMPETITIVE BENCHMARKING 132
10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS 132
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS 132
TABLE 106 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGIONAL FOOTPRINT OF COMPANIES 132
TABLE 107 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES 133
TABLE 108 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 133
10.8 COMPETITIVE SCENARIO 134
10.8.1 PRODUCT LAUNCHES 134
TABLE 109 KEY PRODUCT LAUNCHES 134
10.8.2 DEALS 135
TABLE 110 KEY DEALS 135
11 COMPANY PROFILES 137
11.1 KEY PLAYERS 137
(Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)*
11.1.1 ADAPTIVE BIOTECHNOLOGIES 137
TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW 137
FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021) 138
11.1.2 ARCHERDX (INVITAE CORPORATION) 140
TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW 140
FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021) 141
11.1.3 ASURAGEN, INC. 143
TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW 143
11.1.4 BIO-RAD LABORATORIES, INC. 144
TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 144
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 145
11.1.5 F. HOFFMANN-LA ROCHE AG 147
TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 147
FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 148
11.1.6 GUARDANT HEALTH, INC. 150
TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW 150
FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021) 151
11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC) 154
TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW 154
FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021) 154
11.1.8 INVIVOSCRIBE, INC. 156
TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW 156
11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS 158
TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 158
FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021) 159
11.1.10 NATERA, INC. 161
TABLE 120 NATERA, INC.: BUSINESS OVERVIEW 161
FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021) 162
11.1.11 SYSMEX CORPORATION 163
TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW 163
FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 163
11.2 OTHER PLAYERS 165
11.2.1 NEOGENOMICS LABORATORIES 165
11.2.2 OPKO HEALTH, INC. 167
11.2.3 GENETRON HEALTH 168
11.2.4 QUEST DIAGNOSTICS, INC. 169
11.2.5 ARUP LABORATORIES INC. 170
11.2.6 MISSION BIO, INC. 171
11.2.7 CERGENTIS B.V. 172
*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 173
12.1 DISCUSSION GUIDE 173
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 176
12.3 CUSTOMIZATION OPTIONS 178
12.4 RELATED REPORTS 178
12.5 AUTHOR DETAILS 179